Latest AEZS-108 Stories
QUÃ‰BEC CITY, July 18, 2011 /PRNewswire/ - Aeterna Zentaris Inc.
QUÃ‰BEC CITY, July 7, 2011 /PRNewswire/ - Aeterna Zentaris Inc.
Encouraging trend observed in overall survival with limited side-effects QUEBEC, Nov. 17 /PRNewswire/ - Aeterna Zentaris Inc.
QUEBEC CITY, Nov. 10 /PRNewswire/ - Aeterna Zentaris Inc.
Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris Comprehensive Cancer Center of the University of Southern California QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
Collaboration is part of Aeterna Zentaris' strategy of personalized approach to treatment with AEZS 108, the Company's LHRH receptor targeted conjugate with doxorubicin, being investigated in multiple cancers QUEBEC CITY, June 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
Encouraging trend observed in overall survival QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S.
Preliminary evaluation after completion of treatment phase shows that primary efficacy endpoint has been met for patients with advanced-stage platinum-resistant, taxane-pretreated ovarian cancer. QUEBEC CITY, Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.